DIKD 2 Flashcards
Pathogenesis of what?
- Interaction w/ tubular cell membrane
- increasing permeability & necrosis*
- Reduction in renal blood flow exacerbates ischemia*
Amphotericin B Nephrotoxicity
Presentation of what?
- Nonoliguria (>500ml urine production/day)
- K, Na, Mg wasting*
- Impaired urinary concentration
- Dysfunction apparent in 1-2 weeks*
- Decrease in GFR / Rise in Scr and BUN*
- Damage may be irreversible*
Amphotericin B Nephrotoxicity
What leads to wasting of Na, K, and Mg?
Direct damage of distal tubular membranes–>
Tubular glomerular feedback: further constriction of arterioles–>
Constriction of afferent arterioles leading to decreased glomerular filtration
What “retains” calcium?
Hydrochlorithiazide
Potassium needs to be around what # to be effective?***
4
Risk Factors of what?
- CKD
- Large individual doses
- Large cumulative doses
- Short infusion times
- Volume depletion
- Hypokalemia
- Increased age
- Concomitant diuretics
- Concomitant nephrotoxins
Amphotericin B Nephrotoxicity
How to prevent Amphotericin B Nephrotoxicity
(3 main things)
- Switching from liposomal form in high risk patients**
- Increase infusion time**
-
Alternative antifungal agents**
- Azoles
- Caspofungin
- Low threshold for stopping
- Limit cumulative dose
- Concomitant nephrotoxins
- Hydration
Management of Amphotericin B Nephrotoxicity
(3 things)
- Discontinuation & Substitution
- Monitoring of renal function
- Correct electrolytes as needed
Which drug?
- Toxicity is usually dose dependent
- It causes distal tubular dysfunction (a type 4 renal tubular acidosis) & severe vasoconstriction
- Regular blood level monitoring is important to prevent both acute & chronic nephrotoxicity
- Renal function usually improves after reducing the dose or stopping the drug
Cyclosporine
With patients who are taking ______ to prevent kidney allograft rejection, kidney biopsy is often necessary to distinguish transplant rejection from _______ toxicity.
Cyclosporine / Cyclosporine
Drug Induced Kidney Structural - Functional Alterations:
Hemodynamically Mediated Kidney Injury
What is the treatment?
- ACE-I**
- ARB**
- NSAIDs**
- Cyclosporine, tacrolimus
- OKT3-immunosuppresant (muromonab) (Anti-rejection drugs)
Pathogenesis of what?
- Synthesis of angiotensin II is decreased
- Efferent arteriole remains dilated (mismatch)
- Reduces outflow resistance from the glomerulus
- Decreases hydrostatic pressure in the glomerular capillaries
- Becomes nephrotoxic particularly when renal blood flow is reduced!***
ACE-I and ARB nephrotoxicity
Presentation of what?**
- Decrease in urine output
- Acutely reduces GFR, rise in Scr should be expected
- Scr rise up to 30% within 3-5 days
- desired pharmacologic effect
- Rise associated w/ preservation of renal function
- Stablilizes in 1-2 weeks
- Reversible upon stopping
ACE-I & ARB Nephrotoxicity
What drug blocks prostaglandins?
NSAIDs
- Are located in the stomach lining and kidney
- Involved in afferent blood flow
- NOT involved in efferent blood flow
Good prostaglandins
What drug therapy?
- Synthesis of angiotensin II is decreased
- Preferential dilation of the efferent arteriole
- Reduces outflow resistance from the glomerulus & decreases hydrostatic pressure in the glomerular capillaries
- Alters Starling Forces across the glomerular capillaries to decrease intraglomerular pressure & GFR**
- Leads to nephrotoxicity**
- Particularly in the setting of reduced renal blood flow or effective arterial blood volume in pre-renal settings (CHF)
ACE-I
What drug therapy?
- Afferent & Efferent are affected
- Prostaglandin is NOT affected
- Increase in Scr of 30%
ACE-I
Risk Factors of what toxicity?
-
Patient’s dependent on renal vasoconstriction to maintain BP and GFR*
- Renal Artery Stenosis*
-
Decreased arterial blood volume*
- CHF
- Volume depletion from excess diuresis
- Hepatic cirrhosis w/ ascites
- CKD
- Concurrent use of nephrotoxic drugs
ACE-I and ARB Nephrotoxicity
How to prevent ACE-I and ARB Nephrotoxicity?
(2 things)
-
Choose shorter acting agent in patients at risk
- Captopril, enalapril > lisinopril, benazepril
-
Use low doses w/ gradual titrations
- 2-4 weeks
ACE-I and ARBs can cause what?
Hyperkalemia
Management of ACE-I and ARB Nephrotoxicity
- Discontinue if Scr increases >30% above baseline over 1-2 weeks
- Scr and hyperkalemia will resolve over several days
- Reinitiation can be attempted after correcting volume depletion
(be careful giving older pts NSAIDs bc/ their kidney function is dependent on prostaglandin…)